Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation

Objective: In view of the large variability on therapeutic response and the multiple factors associated to tamoxifen (TAM) metabolic activation, this study aimed to evaluate the effect of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D exposure on TAM metabolism in a group of breast cancer patients. Methods: Trough blood samples were collected from 116 patients. TAM and metabolites endoxifen (EDF), N-desmethyltamoxifen, and 4-hydroxytamoxifen (HTF) were measured in plasma by liquid chromatography–tandem mass spectrometry. CYP2D6 and CYP3A4 phenotyping were obtained according to [dextromethorphan]/[dextrorphan] and [omeprazole]/[omeprazole sulfone] metabolic ratios, measured by high-performance liquid chromatography in plasma collected 3 hours after oral administration of 33 mg of dextromethorphan and 20 mg of omeprazole. Vitamin D3 was measured in plasma by high-performance liquid chromatography–ultraviolet. Data on concomitant use of drug considered as CYP2D6 and CYP3A4 inhibitor or inducer and vitamin D supplementation were recorded. Results: About 20% of patients had reduced CYP2D6 metabolic activity and 7% CYP3A4 impaired metabolism. EDF levels diminished proportionally to the reduction of CYP2D6 metabolic activity (poor metabolizer 2.79 ng·mL−1, intermediate metabolizer (IM) 5.36 ng·mL—1, and extensive metabolizer 10.65 ng·mL−1, P < 0.01). Median plasma levels of TAM (161.50 ng·mL−1) and HTF (1.32 ng·mL−1) in CYP2D6 IM/CYP3A4 poor metabolizer patients were higher (P < 0.05) than those from CYP2D6 IM/CYP3A4 extensive metabolizer patients (122.07 ng·mL−1 and 0.61 ng·mL−1, respectively). Seasons contributed to the interpatient variability of EDF and HTF levels; summer concentrations were 24% and 42% higher compared with winter. Vitamin D3 was not associated to CYP3A4 metabolic activity, indicating that other mechanisms might be involved in the relation between TAM metabolism and vitamin D exposure. Conclusions: CYP3A4 contributes to the bioactivation of TAM through formation of HTF and becomes increasingly important in case of reduced or absent CYP2D6 activity. EDF and HTF exposure were associated to seasonal variations, with considerable higher plasma concentrations during summer.

[1]  V. Haufroid,et al.  CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. , 2015, Pharmacogenomics.

[2]  V. Haufroid,et al.  Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy. , 2015, Talanta.

[3]  M. Hutz,et al.  Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population , 2014, PloS one.

[4]  L. Ekström,et al.  Plasma Levels of 25‐Hydroxyvitamin D3 and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives , 2014, Basic & clinical pharmacology & toxicology.

[5]  J. Beijnen,et al.  Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. , 2014, British journal of clinical pharmacology.

[6]  G. Schwartsmann,et al.  Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. , 2014, Clinical biochemistry.

[7]  S. Ahn,et al.  Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. , 2014, European journal of cancer.

[8]  R. Kim,et al.  Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22 , 2014, Breast Cancer Research and Treatment.

[9]  H. Tedesco-Silva,et al.  CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients , 2013, Clinical pharmacology and therapeutics.

[10]  E. Schuetz,et al.  Interplay between vitamin D and the drug metabolizing enzyme CYP3A4 , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  R. Kim,et al.  CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy , 2013, Breast Cancer Research and Treatment.

[12]  V. Haufroid,et al.  Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype: Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy , 2012, Therapeutic drug monitoring.

[13]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[14]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[16]  J. Lindh,et al.  Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D , 2011, Drug Metabolism and Disposition.

[17]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[18]  F. Musshoff,et al.  Pharmacogenetics and forensic toxicology. , 2010, Forensic science international.

[19]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[20]  H. Brauch,et al.  Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.

[21]  M. Hutz,et al.  Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. , 2009, Pharmacogenomics.

[22]  J. Brockmöller,et al.  CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? / CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug? , 2009 .

[23]  S. Linn,et al.  Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  A. Doehring,et al.  Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? , 2009, PAIN®.

[25]  A. Hofman,et al.  The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.

[26]  Sara Gandini,et al.  Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.

[27]  R. Danesi,et al.  CYP2D6 polymorphisms and the impact on tamoxifen therapy. , 2007, Journal of pharmaceutical sciences.

[28]  Y. Böttiger Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 , 2006, European Journal of Clinical Pharmacology.

[29]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[30]  M. Rouini,et al.  Simple chromatography method for simultaneous determination of dextromethorphan and its main metabolites in human plasma with fluorimetric detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  A. Peregrina,et al.  CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans , 2003, Journal of clinical pharmacology.

[32]  A. Mirshahi,et al.  The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells , 2003, Hepatology.

[33]  J. Bertino,et al.  An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity , 2003, Clinical pharmacology and therapeutics.

[34]  Hyeong-Seok Lim,et al.  Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. , 2014, Pharmacogenomics.

[35]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.

[36]  L. Teh,et al.  Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. , 2012, Drug metabolism and pharmacokinetics.

[37]  L. Teh,et al.  Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance , 2012 .

[38]  M. Meurer,et al.  Vitamin D metabolism , 2010, Dermatologic therapy.

[39]  A. A. Souto,et al.  Simultaneous determination of omeprazole, hydroxyomeprazole and omeprazole sulphone in human plasma by isocratic HPLC-DAD: application to the phenotyping of CYP2C19 and CYP3A4 in brazilian volunteers , 2007 .